Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering-Plough China To Acquire Shanghai Schering-Plough

This article was originally published in PharmAsia News

Executive Summary

The equity transfer of Shanghai Schering-Plough's 45 percent has gone into the final stages of price quotation. According to sources at share-owner Shanghai Pharmaceutical (Group) which is selling its stake, the quotation system still maintains its list price of 66.33 million yuan. Except for original shareholder Schering-Plough China, no other company has submitted application of acceptance; thus, there will be no surprises if Schering-Plough China takes over Shanghai Schering-Plough. So far the equity transaction has started and will be completed at the beginning of July. Shanghai Schering-Plough will then become a wholly-owned subsidiary of a foreign pharmaceutical firm. (Click here for more - Chinese Language)

You may also be interested in...

Schering-Plough Splits With Chinese Joint Venture To Complete Global Organon Merger

Merged company plans expansion throughout China and the Asia-Pacific region.

Schering-Plough Splits With Chinese Joint Venture Partners To Complete Globe-spanning Merger With Organon

BEIJING - Schering-Plough has split with its two joint venture partners in Shanghai in order to complete a worldwide merger with the Netherlands-headquartered Organon BioSciences, according to Schering-Plough executives in the U.S. and China

Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts